Skip to main content
Premium Trial:

Request an Annual Quote

Kalypsys to Provide Screening Technology to NIH Chemical Genomics Center; Deal Worth Up to $30M

NEW YORK, June 9 (GenomeWeb News) - The National Institutes of Health will use screening technology from Kalypsys at its newly created NIH Chemical Genomics Center, the company said today.


The agreement is worth up to $30 million, according to San Diego-based Kalypsys. The Chemical Genomics Center, based at the National Human Genome Research Institute, will use Kalypsys' high throughput screening technology to produce chemical tools to help understand the function of the genome.


The NIH Chemical Genomics Center is the first of up to ten pilot centers established by the Molecular Libraries and Imaging Initiative, led by the National Institute of Mental Health. NIH plans to establish a repository for up to one million chemical compounds. Data generated by the chemical genomics network will be deposited in a freely available central database, called PubChem.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.